HIV-1 Envelope Polypeptides for HIV Vaccine

Immunogenic HIV-1 envelope polypeptides are provided, wherein specificamino acid residues are mutated to repress immunosuppression in GP41, thereby boosting the immune response against HIV-1. Specifically, mutation of those specific residues does not affect the fusogenic propertiesof the viral particleand/or the overall protein structure of the viral envelope protein.The invention further provides peptides and antigens based on the immunogenic HIV-1 envelopes as well as nucleic acid sequences and vectors encoding those. Moreover, biological entities such as viral particles are provided, as well as use of the provided components for preparation of a vaccine against HIV-1/AIDS.

Patents:
CA 2,735,278   [MORE INFO]

Inventor(s): DUCH MOGENS RYTTERGAARD [DK]; PEDERSEN FINN SKOU [DK]; BAHRAMI SHERVIN [DK]; FREDSTED PALLE VILLESEN [DK]; WIUF CARSTEN [DK]; OE

Type of Offer: Sale



« More Medical Patents

---